Celgene Corp (CELG) Tops Q2 EPS by 8c; REVLIMID Sales Rose 13%
Tweet
Share
E-mailGet Alerts CELG Hot Sheet
Price: $108.24 --0%
Financial Fact:
Income tax provision: 85.4M
Today's EPS Names:
CMCT, STEX, PWCM, More
Financial Fact:
Income tax provision: 85.4M
Today's EPS Names:
CMCT, STEX, PWCM, More
Join SI Premium – FREE
Celgene Corp (NASDAQ: CELG) reported Q2 EPS of $1.52, $0.08 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.56 billion versus the consensus estimate of $1.54 billion.
REVLIMID sales up 13 percent to $1.05 billion.
For earnings history and earnings-related data on Celgene Corp (CELG) click here.
REVLIMID sales up 13 percent to $1.05 billion.
For earnings history and earnings-related data on Celgene Corp (CELG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
Create E-mail Alert Related Categories
Earnings, Hot Corp. News, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
